Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens

Background. Efavirenz (EFV), an antiretroviral medication used to treat human immunodeficiency virus (HIV) infection, can increase lipid levels. Because hyperlipidemia is associated with increased risk for cardiovascular (CV) events, this study compared the risk of CV events in patients initiating E...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblatt, Lisa, Farr, Amanda M., Johnston, Stephen S., Nkhoma, Ella T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866551/
https://www.ncbi.nlm.nih.gov/pubmed/27186585
http://dx.doi.org/10.1093/ofid/ofw061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866551/
https://www.ncbi.nlm.nih.gov/pubmed/27186585
http://dx.doi.org/10.1093/ofid/ofw061

Ejemplares similares